GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (FRA:4LN2) » Definitions » Short Percentage of Float

Capricor Therapeutics (FRA:4LN2) Short Percentage of Float


View and export this data going back to 2010. Start your Free Trial

What is Capricor Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Capricor Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Capricor Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Capricor Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Short Percentage of Float falls into.


Capricor Therapeutics (FRA:4LN2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (FRA:4LN2) » Definitions » Short Percentage of Float
Comparable Companies
OBIO GALT YS PBYI OMER BLUE ZVRA ACHV OTLK ATOS OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
CAPR:USA
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Website
https://www.capricor.com
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Capricor Therapeutics (FRA:4LN2) Headlines

No Headlines